Amgen reports Tezspire results as Amgen stock costs EUR 396.08

Published on 10/23/2026 at 11:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Amgen's Tezspire trial posted 68.9 percent remission at week 24. Amgen stock costs EUR 396.08 on October 23, 2026 ahead of November 3 results.

Tezspire results shape the outlook

Tezspire achieved 68.9 percent histologic remission at week 24 on October 20, 2026.
Amgen reported USD 10.05 billion in second-quarter 2026 revenue, up 9.50 percent year over year.
Amgen stock trades at EUR 396.08 at 11:17 a.m. CEST at Lang & Schwarz on October 23, 2026.
Third-quarter results are scheduled for November 3, 2026.

Isometrische 3D-Illustration einer biopharmazeutischen Wertschöpfungskette von Labor bis Vertrieb mit Bioreaktoren — Amgen Inc. (ISIN US0311621009) dargestellt als isometrisches 3D-Diagramm der biopharmazeutischen Wertschöpfungskette von Labor bis Versand, Illustration mit AI erstellt.

Amgen stock (ISIN US0311621009) was at EUR 396.08 at Lang & Schwarz on October 23, 2026 at 11:17 a.m. CEST. The latest company catalyst was positive Phase 3 data for Tezspire in eosinophilic esophagitis, reported on October 20, 2026 by AstraZeneca and Amgen.

Tezspire delivers clinical evidence

The CROSSING trial enrolled 368 patients and tested 210 milligram and 420 milligram doses every four weeks. At week 24, histologic remission reached 64.8 percent with the lower dose and 68.9 percent with the higher dose, compared with 3.5 percent for placebo, according to the October 20 release.

The results also extended to symptoms and endoscopy. At week 52, histologic remission stood at 67.8 percent and 63.3 percent for the two doses, versus 5.4 percent for placebo. Total endoscopic remission reached 34.4 percent and 29.5 percent, compared with 4.1 percent for placebo.

What does the pipeline mean for growth?

Amgen entered the data release with a recent financial base. In the second quarter of 2026, revenue was USD 10.05 billion, up 9.50 percent from the comparable quarter, while adjusted earnings per share reached USD 6.29 against a USD 5.62 consensus estimate, according to Zacks.

Analyst views remain divided. Markets Insider reported on October 13 that Guggenheim cut its target from USD 388.00 to USD 378.00 and kept a Neutral rating. By contrast, Benzinga listed Barclays raising its target from USD 380.00 to USD 400.00 on October 21.

Three milestones frame the story

Amgen reported USD 10.05 billion of second-quarter revenue on August 4, 2026, then Guggenheim cut its target to USD 378.00 on October 13, 2026. The October 20, 2026 Tezspire results supplied the latest clinical milestone with 68.9 percent remission at week 24.

Key dates arrive in November

Amgen lists the European Society of Medical Oncology Congress for October 24, 2026 and its third-quarter 2026 earnings conference call for November 3, 2026. The November report will test whether the company can extend the second-quarter revenue increase into the next reporting period.

Stock valuation meets clinical progress

On the Nasdaq, Amgen closed at USD 447.28 on October 22, 2026. The market capitalization was USD 241.8 billion, and the 52-week range was USD 288.00 to USD 450.98 on the same market-data snapshot.

Amgen was trading at EUR 396.08 at Lang & Schwarz on October 23, 2026 at 11:17 a.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Amgen stock.